title: Tacrolimus (FK506) and methotrexate regimens to prevent graft-versus-host disease after unrelated dog leukocyte antigen (DLA) nonidentical marrow transplantation.
abstract: We previously reported an synergism between methotrexate and tacrolimus (FK506) in preventing graft-versus-host disease (GVHD) in dogs given DLA-nonidentical unrelated marrow grafts after 9.2 Gy of total body irradiation (TBI). Methotrexate was given at 0.4 mg/kg i.v. on days 1, 3, 6 and 11 and FK506 at 0.15 mg/kg/day i.m. on days 0-8 and 0.5 mg/kg/day orally on days 9-90. Half of the dogs became long-term survivors. A major toxicity was gastrointestinal, and 25% of dogs died with intussusception. The current study addresses the problem of intussusception by making changes in drug doses used. In one group of dogs, FK506 was reduced to 0.075 mg/kg i.m. on days 1-8, while methotrexate was administered per original schedule. In a second group, methotrexate was reduced to a single dose on day 7, while FK506 was either administered per the original or reduced-dose schedule. None of the 17 current dogs developed intussusception, however, all but two dogs died with GVHD (n = 12) or graft failure (n = 3). Only two dogs survived after transient GVHD. Results show that there is little room for maneuvering FK506 or methotrexate doses, and hopes of reducing gastrointestinal toxicity by dose modifications while retaining the ability to prevent GVHD were not fulfilled.
authors.affiliation: Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA 98104-2092, USA.
authors.forename: C
authors.initials: C
authors.lastname: Yu
authors.forename: R
authors.initials: R
authors.lastname: Storb
authors.forename: H J
authors.initials: HJ
authors.lastname: Deeg
authors.forename: T C
authors.initials: TC
authors.lastname: Graham
authors.forename: F G
authors.initials: FG
authors.lastname: Scheuning
authors.forename: R
authors.initials: R
authors.lastname: Huss
authors.forename: K
authors.initials: K
authors.lastname: Seidel
authors.forename: W E
authors.initials: WE
authors.lastname: Fitzsimmons
mesh_terms: D000818:Animals; D016026:Bone Marrow Transplantation / Q000009:adverse effects* / Q000276:immunology; D004285:Dogs; D004357:Drug Synergism; D006084:Graft Rejection; D006086:Graft vs Host Disease / Q000209:etiology / Q000517:prevention & control*; D006648:Histocompatibility; D006649:Histocompatibility Antigens / Q000276:immunology*; D007166:Immunosuppressive Agents / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use* / Q000633:toxicity; D007443:Intussusception / Q000139:chemically induced / Q000517:prevention & control; D008727:Methotrexate / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use* / Q000633:toxicity; D011828:Radiation Chimera; D016559:Tacrolimus / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use* / Q000633:toxicity; D019172:Transplantation Conditioning
chemical_list: D006649:Histocompatibility Antigens; D007166:Immunosuppressive Agents; D016559:Tacrolimus; D008727:Methotrexate